Çocukluk Çağında Polisitemia Vera
Özet
Referanslar
Lanzkowsky P. Primary Erythrocytosis. Manual of Pediatric Hematology and Oncology. 6th ed. London: Elsevier Inc;2022. P. 195-97.
Shallis RM, Zeidan AM, Wang R, Podoltsev NA. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2021 Apr;35(2):177-189.
Karakuş S. Polisitemiya Vera. HematoLog 2-1. Türk Hematoloji Derneği, 2012:27-36.
Ohyashiki K, Aota Y, Akahane D, et al. JAK2 (V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia. 2007;21:1097-1099.
Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;335:2452–2466.
Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Blood Rev. 2016 Nov;30(6):453-459.
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 Dec;95(12):1599-1613.
Referanslar
Lanzkowsky P. Primary Erythrocytosis. Manual of Pediatric Hematology and Oncology. 6th ed. London: Elsevier Inc;2022. P. 195-97.
Shallis RM, Zeidan AM, Wang R, Podoltsev NA. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2021 Apr;35(2):177-189.
Karakuş S. Polisitemiya Vera. HematoLog 2-1. Türk Hematoloji Derneği, 2012:27-36.
Ohyashiki K, Aota Y, Akahane D, et al. JAK2 (V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia. 2007;21:1097-1099.
Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;335:2452–2466.
Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Blood Rev. 2016 Nov;30(6):453-459.
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 Dec;95(12):1599-1613.
